European expert consensus statement on therapeutic goals in Fabry disease

2018/06/12 by Christoph Wanner, Michael Arad, Ralf Baron +32 · 2 citations
Medicine · #Glycogen Storage Diseases and Myoclonus #Law #Lysosomal Storage Disorders Research #Medicine #Political science #Statement (logic) #Whipple's Disease and Interleukins

paper · doi:10.1016/j.ymgme.2018.06.004

openalex publication_date 2018/06/12 · crossref created 2018/06/12 · crossref issued 2018/07/01 · crossref published 2018/07/01 · crossref published-print 2018/07/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/21 · crossref indexed 2026/07/13 · openalex updated_date 2026/08/05

Citations

• Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry Disease
• Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry
• 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
• Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
• 2013 ESH/ESC Guidelines for the management of arterial hypertension
• A New Equation to Estimate Glomerular Filtration Rate
• Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Cited by

• Fabry disease in cardiology practice: Literature review and expert point of view
• Fabry disease [wikipedia]